Sushmita Panda is a New Delhi-based journalist with over six years of experience covering the healthcare and pharmaceutical sectors. She has reported on critical issues including drug patents and discovery, rare diseases, innovative therapies, women’s health, Neglected Tropical Diseases (NTDs), mental health, drug access, and regulatory affairs. Over the years, she has authored numerous in-depth stories and on-ground reports on diseases prevalent in India, including several exclusives and interviews with industry leaders. An alumna of the Asian College of Journalism and the University of Delhi, Sushmita has worked with national and international publications such as Financial Express, Sputnik, The Sunday Guardian, and India TV. When she’s not chasing stories, she enjoys reading and exploring new places.
Latest from Sushmita Panda
Attention now shifts to the company’s review of unblinded data and whether changes to patient enrolment could support further evaluation.
Despite the positive update, uncertainty regarding the future of Intellia's second Phase III trial for nex-z, which is till on hold, remains.
Roche's CT-388 shows promise in Phase II obesity trial but analysts question "commercial relevance" in a crowded market.
IO Biotech is evaluating a further reduction-in-force as it begins a strategic alternatives review following regulatory setbacks to its lead melanoma program.
Valneva's withdrawal of its chikungunya vaccine leaves Bavarian Nordic as the only remaining firm producing a shot for the condition in the US.
AI-related deal activity in the fourth quarter of 2025 brought a broad mix of financing rounds, acquisitions and strategic collaborations.